Ultragenyx Pharmaceutical Inc. (RARE) Stock Competitors & Peer Comparison
See (RARE) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| RARE | $24.35 | +1.54% | 2.4B | -3.99 | -$6.10 | N/A |
| NVO | $43.88 | -0.18% | 195B | 10.30 | $4.26 | +4.07% |
| VRTX | $444.93 | -0.02% | 112.9B | 26.37 | $16.87 | N/A |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| REGN | $612.14 | +0.11% | 63.1B | 14.94 | $40.97 | +0.59% |
| ARGX | $893.52 | -0.60% | 55.3B | 39.71 | $22.50 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ALNY | $282.85 | -2.26% | 37.8B | 70.89 | $3.99 | N/A |
| RVMDW | $5.94 | +7.51% | 36.1B | N/A | N/A | N/A |
| RVMD | $153.87 | +3.11% | 32.7B | -21.64 | -$7.11 | N/A |
Stock Comparison
RARE vs NVO Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, NVO has a market cap of 195B. Regarding current trading prices, RARE is priced at $24.35, while NVO trades at $43.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas NVO's P/E ratio is 10.30. In terms of profitability, RARE's ROE is +15.67%, compared to NVO's ROE of +0.66%. Regarding short-term risk, RARE is more volatile compared to NVO. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check NVO's competition here
RARE vs VRTX Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, VRTX has a market cap of 112.9B. Regarding current trading prices, RARE is priced at $24.35, while VRTX trades at $444.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas VRTX's P/E ratio is 26.37. In terms of profitability, RARE's ROE is +15.67%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, RARE is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check VRTX's competition here
RARE vs VRNA Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, RARE is priced at $24.35, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas VRNA's P/E ratio is -102.80. In terms of profitability, RARE's ROE is +15.67%, compared to VRNA's ROE of -0.13%. Regarding short-term risk, RARE is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check VRNA's competition here
RARE vs REGN Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, REGN has a market cap of 63.1B. Regarding current trading prices, RARE is priced at $24.35, while REGN trades at $612.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas REGN's P/E ratio is 14.94. In terms of profitability, RARE's ROE is +15.67%, compared to REGN's ROE of +0.14%. Regarding short-term risk, RARE is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check REGN's competition here
RARE vs ARGX Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, ARGX has a market cap of 55.3B. Regarding current trading prices, RARE is priced at $24.35, while ARGX trades at $893.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas ARGX's P/E ratio is 39.71. In terms of profitability, RARE's ROE is +15.67%, compared to ARGX's ROE of +0.37%. Regarding short-term risk, RARE is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check ARGX's competition here
RARE vs SGEN Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, RARE is priced at $24.35, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas SGEN's P/E ratio is -57.19. In terms of profitability, RARE's ROE is +15.67%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, RARE is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check SGEN's competition here
RARE vs ALNY Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, ALNY has a market cap of 37.8B. Regarding current trading prices, RARE is priced at $24.35, while ALNY trades at $282.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas ALNY's P/E ratio is 70.89. In terms of profitability, RARE's ROE is +15.67%, compared to ALNY's ROE of +0.98%. Regarding short-term risk, RARE is less volatile compared to ALNY. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check ALNY's competition here
RARE vs RVMDW Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, RVMDW has a market cap of 36.1B. Regarding current trading prices, RARE is priced at $24.35, while RVMDW trades at $5.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas RVMDW's P/E ratio is N/A. In terms of profitability, RARE's ROE is +15.67%, compared to RVMDW's ROE of -0.83%. Regarding short-term risk, RARE is less volatile compared to RVMDW. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check RVMDW's competition here
RARE vs RVMD Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, RVMD has a market cap of 32.7B. Regarding current trading prices, RARE is priced at $24.35, while RVMD trades at $153.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas RVMD's P/E ratio is -21.64. In terms of profitability, RARE's ROE is +15.67%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, RARE is less volatile compared to RVMD. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check RVMD's competition here
RARE vs RPRX Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, RPRX has a market cap of 23.6B. Regarding current trading prices, RARE is priced at $24.35, while RPRX trades at $54.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas RPRX's P/E ratio is 28.88. In terms of profitability, RARE's ROE is +15.67%, compared to RPRX's ROE of +0.13%. Regarding short-term risk, RARE is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check RPRX's competition here
RARE vs UTHR Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, UTHR has a market cap of 23.2B. Regarding current trading prices, RARE is priced at $24.35, while UTHR trades at $545.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas UTHR's P/E ratio is 20.18. In terms of profitability, RARE's ROE is +15.67%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, RARE is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check UTHR's competition here
RARE vs BNTX Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, BNTX has a market cap of 22.9B. Regarding current trading prices, RARE is priced at $24.35, while BNTX trades at $90.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas BNTX's P/E ratio is -15.50. In terms of profitability, RARE's ROE is +15.67%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, RARE is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check BNTX's competition here
RARE vs INCY Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, INCY has a market cap of 21.7B. Regarding current trading prices, RARE is priced at $24.35, while INCY trades at $108.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas INCY's P/E ratio is 15.33. In terms of profitability, RARE's ROE is +15.67%, compared to INCY's ROE of +0.29%. Regarding short-term risk, RARE is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check INCY's competition here
RARE vs ROIV Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, ROIV has a market cap of 21.6B. Regarding current trading prices, RARE is priced at $24.35, while ROIV trades at $30.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas ROIV's P/E ratio is -55.63. In terms of profitability, RARE's ROE is +15.67%, compared to ROIV's ROE of -0.07%. Regarding short-term risk, RARE is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check ROIV's competition here
RARE vs INSM Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, INSM has a market cap of 21.2B. Regarding current trading prices, RARE is priced at $24.35, while INSM trades at $97.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas INSM's P/E ratio is -16.99. In terms of profitability, RARE's ROE is +15.67%, compared to INSM's ROE of -1.30%. Regarding short-term risk, RARE is less volatile compared to INSM. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check INSM's competition here
RARE vs BGNE Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, RARE is priced at $24.35, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas BGNE's P/E ratio is -22.55. In terms of profitability, RARE's ROE is +15.67%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, RARE is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check BGNE's competition here
RARE vs MRNA Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, MRNA has a market cap of 19.8B. Regarding current trading prices, RARE is priced at $24.35, while MRNA trades at $49.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas MRNA's P/E ratio is -6.13. In terms of profitability, RARE's ROE is +15.67%, compared to MRNA's ROE of -0.37%. Regarding short-term risk, RARE is less volatile compared to MRNA. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check MRNA's competition here
RARE vs DNA-WT Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, RARE is priced at $24.35, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, RARE's ROE is +15.67%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, RARE is less volatile compared to DNA-WT. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check DNA-WT's competition here
RARE vs NBIX Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, NBIX has a market cap of 16.1B. Regarding current trading prices, RARE is priced at $24.35, while NBIX trades at $159.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas NBIX's P/E ratio is 24.62. In terms of profitability, RARE's ROE is +15.67%, compared to NBIX's ROE of +0.22%. Regarding short-term risk, RARE is more volatile compared to NBIX. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check NBIX's competition here
RARE vs GMAB Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, GMAB has a market cap of 15.4B. Regarding current trading prices, RARE is priced at $24.35, while GMAB trades at $25.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas GMAB's P/E ratio is 19.00. In terms of profitability, RARE's ROE is +15.67%, compared to GMAB's ROE of +0.15%. Regarding short-term risk, RARE is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check GMAB's competition here
RARE vs JAZZ Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, JAZZ has a market cap of 14.5B. Regarding current trading prices, RARE is priced at $24.35, while JAZZ trades at $230.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas JAZZ's P/E ratio is 2096.00. In terms of profitability, RARE's ROE is +15.67%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, RARE is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check JAZZ's competition here
RARE vs ASND Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, ASND has a market cap of 13.5B. Regarding current trading prices, RARE is priced at $24.35, while ASND trades at $218.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas ASND's P/E ratio is 25.01. In terms of profitability, RARE's ROE is +15.67%, compared to ASND's ROE of -56.42%. Regarding short-term risk, RARE is less volatile compared to ASND. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check ASND's competition here
RARE vs EXEL Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, EXEL has a market cap of 13.4B. Regarding current trading prices, RARE is priced at $24.35, while EXEL trades at $53.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas EXEL's P/E ratio is 17.59. In terms of profitability, RARE's ROE is +15.67%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, RARE is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check EXEL's competition here
RARE vs AXSM Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, AXSM has a market cap of 13.1B. Regarding current trading prices, RARE is priced at $24.35, while AXSM trades at $255.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas AXSM's P/E ratio is -68.59. In terms of profitability, RARE's ROE is +15.67%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, RARE is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check AXSM's competition here
RARE vs BBIO Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, BBIO has a market cap of 13.1B. Regarding current trading prices, RARE is priced at $24.35, while BBIO trades at $66.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas BBIO's P/E ratio is -17.86. In terms of profitability, RARE's ROE is +15.67%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, RARE is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check BBIO's competition here
RARE vs KRTX Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, RARE is priced at $24.35, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas KRTX's P/E ratio is -28.09. In terms of profitability, RARE's ROE is +15.67%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, RARE is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check KRTX's competition here
RARE vs IONS Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, IONS has a market cap of 12.1B. Regarding current trading prices, RARE is priced at $24.35, while IONS trades at $73.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas IONS's P/E ratio is -36.46. In terms of profitability, RARE's ROE is +15.67%, compared to IONS's ROE of -0.59%. Regarding short-term risk, RARE is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check IONS's competition here
RARE vs RNAM Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, RARE is priced at $24.35, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas RNAM's P/E ratio is -17.39. In terms of profitability, RARE's ROE is +15.67%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, RARE is more volatile compared to RNAM. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check RNAM's competition here
RARE vs MDGL Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, MDGL has a market cap of 11.1B. Regarding current trading prices, RARE is priced at $24.35, while MDGL trades at $480.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas MDGL's P/E ratio is -35.59. In terms of profitability, RARE's ROE is +15.67%, compared to MDGL's ROE of -0.50%. Regarding short-term risk, RARE is less volatile compared to MDGL. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check MDGL's competition here
RARE vs SMMT Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, SMMT has a market cap of 10.9B. Regarding current trading prices, RARE is priced at $24.35, while SMMT trades at $14.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas SMMT's P/E ratio is -8.81. In terms of profitability, RARE's ROE is +15.67%, compared to SMMT's ROE of -3.41%. Regarding short-term risk, RARE is less volatile compared to SMMT. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check SMMT's competition here
RARE vs BMRN Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, BMRN has a market cap of 10.8B. Regarding current trading prices, RARE is priced at $24.35, while BMRN trades at $55.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas BMRN's P/E ratio is 40.25. In terms of profitability, RARE's ROE is +15.67%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, RARE is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check BMRN's competition here
RARE vs ARWR Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, ARWR has a market cap of 10.5B. Regarding current trading prices, RARE is priced at $24.35, while ARWR trades at $74.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas ARWR's P/E ratio is -32.83. In terms of profitability, RARE's ROE is +15.67%, compared to ARWR's ROE of -0.55%. Regarding short-term risk, RARE is more volatile compared to ARWR. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check ARWR's competition here
RARE vs RXDX Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, RARE is priced at $24.35, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas RXDX's P/E ratio is -56.47. In terms of profitability, RARE's ROE is +15.67%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, RARE is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check RXDX's competition here
RARE vs KRYS Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, KRYS has a market cap of 9.4B. Regarding current trading prices, RARE is priced at $24.35, while KRYS trades at $317.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas KRYS's P/E ratio is 42.57. In terms of profitability, RARE's ROE is +15.67%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, RARE is less volatile compared to KRYS. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check KRYS's competition here
RARE vs NUVL Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, RARE is priced at $24.35, while NUVL trades at $123.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas NUVL's P/E ratio is -20.34. In terms of profitability, RARE's ROE is +15.67%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, RARE is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check NUVL's competition here
RARE vs CORT Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, CORT has a market cap of 8.9B. Regarding current trading prices, RARE is priced at $24.35, while CORT trades at $82.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas CORT's P/E ratio is 236.89. In terms of profitability, RARE's ROE is +15.67%, compared to CORT's ROE of +0.08%. Regarding short-term risk, RARE is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check CORT's competition here
RARE vs CYTK Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, CYTK has a market cap of 8.7B. Regarding current trading prices, RARE is priced at $24.35, while CYTK trades at $70.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas CYTK's P/E ratio is -10.24. In terms of profitability, RARE's ROE is +15.67%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, RARE is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check CYTK's competition here
RARE vs IMGN Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, RARE is priced at $24.35, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas IMGN's P/E ratio is -111.55. In terms of profitability, RARE's ROE is +15.67%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, RARE is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check IMGN's competition here
RARE vs TECH Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, TECH has a market cap of 8.5B. Regarding current trading prices, RARE is priced at $24.35, while TECH trades at $54.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas TECH's P/E ratio is 77.14. In terms of profitability, RARE's ROE is +15.67%, compared to TECH's ROE of +0.05%. Regarding short-term risk, RARE is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check TECH's competition here
RARE vs BPMC Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, RARE is priced at $24.35, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas BPMC's P/E ratio is -51.58. In terms of profitability, RARE's ROE is +15.67%, compared to BPMC's ROE of -0.15%. Regarding short-term risk, RARE is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check BPMC's competition here
RARE vs HALO Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, HALO has a market cap of 8.2B. Regarding current trading prices, RARE is priced at $24.35, while HALO trades at $69.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas HALO's P/E ratio is 24.39. In terms of profitability, RARE's ROE is +15.67%, compared to HALO's ROE of +1.26%. Regarding short-term risk, RARE is less volatile compared to HALO. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check HALO's competition here
RARE vs CERE Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, RARE is priced at $24.35, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas CERE's P/E ratio is -16.47. In terms of profitability, RARE's ROE is +15.67%, compared to CERE's ROE of -0.72%. Regarding short-term risk, RARE is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check CERE's competition here
RARE vs TGTX Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, TGTX has a market cap of 7.6B. Regarding current trading prices, RARE is priced at $24.35, while TGTX trades at $49.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas TGTX's P/E ratio is 17.31. In terms of profitability, RARE's ROE is +15.67%, compared to TGTX's ROE of +0.87%. Regarding short-term risk, RARE is less volatile compared to TGTX. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check TGTX's competition here
RARE vs IBRX Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, IBRX has a market cap of 7.4B. Regarding current trading prices, RARE is priced at $24.35, while IBRX trades at $7.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas IBRX's P/E ratio is -8.35. In terms of profitability, RARE's ROE is +15.67%, compared to IBRX's ROE of +1.39%. Regarding short-term risk, RARE is less volatile compared to IBRX. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check IBRX's competition here
RARE vs MTSR Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, RARE is priced at $24.35, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas MTSR's P/E ratio is -23.58. In terms of profitability, RARE's ROE is +15.67%, compared to MTSR's ROE of -0.80%. Regarding short-term risk, RARE is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check MTSR's competition here
RARE vs ALKS Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, ALKS has a market cap of 7.4B. Regarding current trading prices, RARE is priced at $24.35, while ALKS trades at $44.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas ALKS's P/E ratio is 49.20. In terms of profitability, RARE's ROE is +15.67%, compared to ALKS's ROE of +0.09%. Regarding short-term risk, RARE is less volatile compared to ALKS. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check ALKS's competition here
RARE vs KYMR Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, KYMR has a market cap of 7.1B. Regarding current trading prices, RARE is priced at $24.35, while KYMR trades at $86.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas KYMR's P/E ratio is -24.08. In terms of profitability, RARE's ROE is +15.67%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, RARE is less volatile compared to KYMR. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check KYMR's competition here
RARE vs PTGX Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, PTGX has a market cap of 7.1B. Regarding current trading prices, RARE is priced at $24.35, while PTGX trades at $109.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas PTGX's P/E ratio is -60.65. In terms of profitability, RARE's ROE is +15.67%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, RARE is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check PTGX's competition here
RARE vs IMVT Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, IMVT has a market cap of 6.9B. Regarding current trading prices, RARE is priced at $24.35, while IMVT trades at $33.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas IMVT's P/E ratio is -12.14. In terms of profitability, RARE's ROE is +15.67%, compared to IMVT's ROE of -0.68%. Regarding short-term risk, RARE is less volatile compared to IMVT. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check IMVT's competition here
RARE vs PCVX Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, PCVX has a market cap of 6.9B. Regarding current trading prices, RARE is priced at $24.35, while PCVX trades at $47.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas PCVX's P/E ratio is -6.89. In terms of profitability, RARE's ROE is +15.67%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, RARE is less volatile compared to PCVX. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check PCVX's competition here
RARE vs MRUS Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, RARE is priced at $24.35, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas MRUS's P/E ratio is -17.05. In terms of profitability, RARE's ROE is +15.67%, compared to MRUS's ROE of -0.51%. Regarding short-term risk, RARE is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check MRUS's competition here
RARE vs ACLX Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, RARE is priced at $24.35, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas ACLX's P/E ratio is -28.27. In terms of profitability, RARE's ROE is +15.67%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, RARE is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check ACLX's competition here
RARE vs LEGN Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, LEGN has a market cap of 6.6B. Regarding current trading prices, RARE is priced at $24.35, while LEGN trades at $35.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas LEGN's P/E ratio is -25.99. In terms of profitability, RARE's ROE is +15.67%, compared to LEGN's ROE of -0.25%. Regarding short-term risk, RARE is less volatile compared to LEGN. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check LEGN's competition here
RARE vs RETA Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, RARE is priced at $24.35, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas RETA's P/E ratio is -66.29. In terms of profitability, RARE's ROE is +15.67%, compared to RETA's ROE of +0.47%. Regarding short-term risk, RARE is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check RETA's competition here
RARE vs LQDA Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, LQDA has a market cap of 6.3B. Regarding current trading prices, RARE is priced at $24.35, while LQDA trades at $71.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas LQDA's P/E ratio is 419.00. In terms of profitability, RARE's ROE is +15.67%, compared to LQDA's ROE of +0.47%. Regarding short-term risk, RARE is more volatile compared to LQDA. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check LQDA's competition here
RARE vs ABVX Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, ABVX has a market cap of 6.3B. Regarding current trading prices, RARE is priced at $24.35, while ABVX trades at $96.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas ABVX's P/E ratio is -18.15. In terms of profitability, RARE's ROE is +15.67%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, RARE is less volatile compared to ABVX. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check ABVX's competition here
RARE vs PTCT Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, PTCT has a market cap of 6.2B. Regarding current trading prices, RARE is priced at $24.35, while PTCT trades at $75.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas PTCT's P/E ratio is -29.58. In terms of profitability, RARE's ROE is +15.67%, compared to PTCT's ROE of +1.00%. Regarding short-term risk, RARE is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check PTCT's competition here
RARE vs CNTA Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, CNTA has a market cap of 6.1B. Regarding current trading prices, RARE is priced at $24.35, while CNTA trades at $39.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas CNTA's P/E ratio is -22.31. In terms of profitability, RARE's ROE is +15.67%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, RARE is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check CNTA's competition here
RARE vs RYTM Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, RYTM has a market cap of 6.1B. Regarding current trading prices, RARE is priced at $24.35, while RYTM trades at $88.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas RYTM's P/E ratio is -28.24. In terms of profitability, RARE's ROE is +15.67%, compared to RYTM's ROE of -2.03%. Regarding short-term risk, RARE is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check RYTM's competition here
RARE vs COGT Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, COGT has a market cap of 5.7B. Regarding current trading prices, RARE is priced at $24.35, while COGT trades at $33.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas COGT's P/E ratio is -15.25. In terms of profitability, RARE's ROE is +15.67%, compared to COGT's ROE of -0.83%. Regarding short-term risk, RARE is less volatile compared to COGT. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check COGT's competition here
RARE vs PRAX Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, PRAX has a market cap of 5.6B. Regarding current trading prices, RARE is priced at $24.35, while PRAX trades at $266.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas PRAX's P/E ratio is -19.92. In terms of profitability, RARE's ROE is +15.67%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, RARE is less volatile compared to PRAX. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check PRAX's competition here
RARE vs CDTX Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, RARE is priced at $24.35, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas CDTX's P/E ratio is -19.77. In terms of profitability, RARE's ROE is +15.67%, compared to CDTX's ROE of -0.60%. Regarding short-term risk, RARE is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check CDTX's competition here
RARE vs BLTE Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, BLTE has a market cap of 5.5B. Regarding current trading prices, RARE is priced at $24.35, while BLTE trades at $138.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas BLTE's P/E ratio is -54.39. In terms of profitability, RARE's ROE is +15.67%, compared to BLTE's ROE of -0.27%. Regarding short-term risk, RARE is more volatile compared to BLTE. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check BLTE's competition here
RARE vs ABCM Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, RARE is priced at $24.35, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, RARE's ROE is +15.67%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, RARE is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check ABCM's competition here
RARE vs ISEE Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, RARE is priced at $24.35, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas ISEE's P/E ratio is -22.44. In terms of profitability, RARE's ROE is +15.67%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, RARE is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check ISEE's competition here
RARE vs APGE Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, APGE has a market cap of 5.5B. Regarding current trading prices, RARE is priced at $24.35, while APGE trades at $88.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas APGE's P/E ratio is -20.40. In terms of profitability, RARE's ROE is +15.67%, compared to APGE's ROE of -0.33%. Regarding short-term risk, RARE is less volatile compared to APGE. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check APGE's competition here
RARE vs FBIOX Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, FBIOX has a market cap of 5.3B. Regarding current trading prices, RARE is priced at $24.35, while FBIOX trades at $25.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas FBIOX's P/E ratio is N/A. In terms of profitability, RARE's ROE is +15.67%, compared to FBIOX's ROE of N/A. Regarding short-term risk, RARE is more volatile compared to FBIOX. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check FBIOX's competition here
RARE vs SRRK Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, SRRK has a market cap of 5.3B. Regarding current trading prices, RARE is priced at $24.35, while SRRK trades at $44.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas SRRK's P/E ratio is -12.81. In terms of profitability, RARE's ROE is +15.67%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, RARE is less volatile compared to SRRK. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check SRRK's competition here
RARE vs CGON Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, CGON has a market cap of 5.3B. Regarding current trading prices, RARE is priced at $24.35, while CGON trades at $59.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas CGON's P/E ratio is -25.45. In terms of profitability, RARE's ROE is +15.67%, compared to CGON's ROE of -0.23%. Regarding short-term risk, RARE is less volatile compared to CGON. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check CGON's competition here
RARE vs APLS Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, RARE is priced at $24.35, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas APLS's P/E ratio is 38.35. In terms of profitability, RARE's ROE is +15.67%, compared to APLS's ROE of +0.40%. Regarding short-term risk, RARE is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check APLS's competition here
RARE vs LGND Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, LGND has a market cap of 5.1B. Regarding current trading prices, RARE is priced at $24.35, while LGND trades at $255.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas LGND's P/E ratio is 33.36. In terms of profitability, RARE's ROE is +15.67%, compared to LGND's ROE of +0.16%. Regarding short-term risk, RARE is less volatile compared to LGND. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check LGND's competition here
RARE vs CAI Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, CAI has a market cap of 5.1B. Regarding current trading prices, RARE is priced at $24.35, while CAI trades at $17.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas CAI's P/E ratio is -6.51. In terms of profitability, RARE's ROE is +15.67%, compared to CAI's ROE of +0.06%. Regarding short-term risk, RARE is less volatile compared to CAI. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check CAI's competition here
RARE vs MIRM Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, MIRM has a market cap of 5B. Regarding current trading prices, RARE is priced at $24.35, while MIRM trades at $99.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas MIRM's P/E ratio is -7.30. In terms of profitability, RARE's ROE is +15.67%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, RARE is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check MIRM's competition here
RARE vs SYRE Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, SYRE has a market cap of 4.9B. Regarding current trading prices, RARE is priced at $24.35, while SYRE trades at $80.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas SYRE's P/E ratio is -38.11. In terms of profitability, RARE's ROE is +15.67%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, RARE is less volatile compared to SYRE. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check SYRE's competition here
RARE vs TVTX Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, TVTX has a market cap of 4.8B. Regarding current trading prices, RARE is priced at $24.35, while TVTX trades at $52.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas TVTX's P/E ratio is -104.08. In terms of profitability, RARE's ROE is +15.67%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, RARE is less volatile compared to TVTX. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check TVTX's competition here
RARE vs CRSP Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, CRSP has a market cap of 4.8B. Regarding current trading prices, RARE is priced at $24.35, while CRSP trades at $49.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas CRSP's P/E ratio is -8.07. In terms of profitability, RARE's ROE is +15.67%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, RARE is more volatile compared to CRSP. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check CRSP's competition here
RARE vs TERN Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, RARE is priced at $24.35, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas TERN's P/E ratio is -51.41. In terms of profitability, RARE's ROE is +15.67%, compared to TERN's ROE of -0.20%. Regarding short-term risk, RARE is more volatile compared to TERN. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check TERN's competition here
RARE vs FOLD Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, RARE is priced at $24.35, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas FOLD's P/E ratio is -161.00. In terms of profitability, RARE's ROE is +15.67%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, RARE is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check FOLD's competition here
RARE vs AKRO Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, RARE is priced at $24.35, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas AKRO's P/E ratio is -14.57. In terms of profitability, RARE's ROE is +15.67%, compared to AKRO's ROE of -0.31%. Regarding short-term risk, RARE is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check AKRO's competition here
RARE vs ALPN Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, RARE is priced at $24.35, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas ALPN's P/E ratio is -101.52. In terms of profitability, RARE's ROE is +15.67%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, RARE is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check ALPN's competition here
RARE vs ERAS Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, ERAS has a market cap of 4.4B. Regarding current trading prices, RARE is priced at $24.35, while ERAS trades at $14.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas ERAS's P/E ratio is -15.11. In terms of profitability, RARE's ROE is +15.67%, compared to ERAS's ROE of -0.77%. Regarding short-term risk, RARE is less volatile compared to ERAS. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check ERAS's competition here
RARE vs CELC Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, CELC has a market cap of 4.3B. Regarding current trading prices, RARE is priced at $24.35, while CELC trades at $88.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas CELC's P/E ratio is -22.71. In terms of profitability, RARE's ROE is +15.67%, compared to CELC's ROE of -2.45%. Regarding short-term risk, RARE is less volatile compared to CELC. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check CELC's competition here
RARE vs OPT Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, RARE is priced at $24.35, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas OPT's P/E ratio is -1.52. In terms of profitability, RARE's ROE is +15.67%, compared to OPT's ROE of +1.09%. Regarding short-term risk, RARE is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check OPT's competition here
RARE vs XENE Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, XENE has a market cap of 4.2B. Regarding current trading prices, RARE is priced at $24.35, while XENE trades at $52.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas XENE's P/E ratio is -11.23. In terms of profitability, RARE's ROE is +15.67%, compared to XENE's ROE of -0.49%. Regarding short-term risk, RARE is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check XENE's competition here
RARE vs MRTX Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, RARE is priced at $24.35, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas MRTX's P/E ratio is -4.82. In terms of profitability, RARE's ROE is +15.67%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, RARE is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check MRTX's competition here
RARE vs MANE Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, MANE has a market cap of 4B. Regarding current trading prices, RARE is priced at $24.35, while MANE trades at $96.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas MANE's P/E ratio is -36.32. In terms of profitability, RARE's ROE is +15.67%, compared to MANE's ROE of -0.95%. Regarding short-term risk, RARE is less volatile compared to MANE. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check MANE's competition here
RARE vs KNSA Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, KNSA has a market cap of 3.9B. Regarding current trading prices, RARE is priced at $24.35, while KNSA trades at $51.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas KNSA's P/E ratio is 57.02. In terms of profitability, RARE's ROE is +15.67%, compared to KNSA's ROE of +0.13%. Regarding short-term risk, RARE is more volatile compared to KNSA. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check KNSA's competition here
RARE vs CPRX Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, CPRX has a market cap of 3.8B. Regarding current trading prices, RARE is priced at $24.35, while CPRX trades at $31.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas CPRX's P/E ratio is 18.13. In terms of profitability, RARE's ROE is +15.67%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, RARE is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check CPRX's competition here
RARE vs VCYT Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, VCYT has a market cap of 3.8B. Regarding current trading prices, RARE is priced at $24.35, while VCYT trades at $47.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas VCYT's P/E ratio is 43.82. In terms of profitability, RARE's ROE is +15.67%, compared to VCYT's ROE of +0.07%. Regarding short-term risk, RARE is less volatile compared to VCYT. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check VCYT's competition here
RARE vs RYZB Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, RARE is priced at $24.35, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas RYZB's P/E ratio is -57.86. In terms of profitability, RARE's ROE is +15.67%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, RARE is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check RYZB's competition here
RARE vs EWTX Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, EWTX has a market cap of 3.7B. Regarding current trading prices, RARE is priced at $24.35, while EWTX trades at $34.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas EWTX's P/E ratio is -20.98. In terms of profitability, RARE's ROE is +15.67%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, RARE is less volatile compared to EWTX. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check EWTX's competition here
RARE vs CBAY Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, RARE is priced at $24.35, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas CBAY's P/E ratio is -32.81. In terms of profitability, RARE's ROE is +15.67%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, RARE is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check CBAY's competition here
RARE vs CRNX Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, CRNX has a market cap of 3.6B. Regarding current trading prices, RARE is priced at $24.35, while CRNX trades at $34.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas CRNX's P/E ratio is -6.71. In terms of profitability, RARE's ROE is +15.67%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, RARE is less volatile compared to CRNX. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check CRNX's competition here
RARE vs ACAD Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, ACAD has a market cap of 3.6B. Regarding current trading prices, RARE is priced at $24.35, while ACAD trades at $21.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas ACAD's P/E ratio is 9.81. In terms of profitability, RARE's ROE is +15.67%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, RARE is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check ACAD's competition here
RARE vs TNGX Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, TNGX has a market cap of 3.6B. Regarding current trading prices, RARE is priced at $24.35, while TNGX trades at $30.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas TNGX's P/E ratio is -37.28. In terms of profitability, RARE's ROE is +15.67%, compared to TNGX's ROE of -0.42%. Regarding short-term risk, RARE is less volatile compared to TNGX. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check TNGX's competition here
RARE vs NAMS Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, NAMS has a market cap of 3.6B. Regarding current trading prices, RARE is priced at $24.35, while NAMS trades at $30.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas NAMS's P/E ratio is -17.08. In terms of profitability, RARE's ROE is +15.67%, compared to NAMS's ROE of -0.30%. Regarding short-term risk, RARE is less volatile compared to NAMS. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check NAMS's competition here
RARE vs SWTX Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, RARE is priced at $24.35, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas SWTX's P/E ratio is -13.78. In terms of profitability, RARE's ROE is +15.67%, compared to SWTX's ROE of -0.36%. Regarding short-term risk, RARE is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check SWTX's competition here
RARE vs DNLI Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, DNLI has a market cap of 3.4B. Regarding current trading prices, RARE is priced at $24.35, while DNLI trades at $21.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas DNLI's P/E ratio is -7.52. In terms of profitability, RARE's ROE is +15.67%, compared to DNLI's ROE of -0.52%. Regarding short-term risk, RARE is less volatile compared to DNLI. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check DNLI's competition here
RARE vs DNTH Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.4B. In comparison, DNTH has a market cap of 3.4B. Regarding current trading prices, RARE is priced at $24.35, while DNTH trades at $82.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.99, whereas DNTH's P/E ratio is -19.40. In terms of profitability, RARE's ROE is +15.67%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, RARE is less volatile compared to DNTH. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check DNTH's competition here